Dr. Hemmel Amrania YC21 is the founder of Digistain. A platform cancer diagnostics technology that promises to eliminate the overuse of cytotoxic chemotherapy. Dr. Hemmel Amrania YC21 is the founder of Digistain. A platform cancer diagnostics technology that promises to eliminate the overuse of cytotoxic chemotherapy. He is a world-leading expert in infrared imaging. He holds the degrees of MSc and PhD in Physics from SupOptique, Paris, and Imperial College London, where his work as a Post Doctorate Researcher in the field of laser-based medical imaging saw him file for 7 patents and receive the Imperial College's Outstanding Research Prize as well as the Royal Society Innovation Award for his contribution to breast cancer imaging. He spear-headed Digistain's R&D from its beginnings in a physics lab, securing both public and private funding for clinical trials all the way to clinical deployment. Hemmel’s specialities include Quantum Detection, Microscopic Optics, Infra-red, Laser, Multispectral, and Chemical Imaging on which he is the contributor for the book Vibrational Spectroscopy for Biomedical Applications. His cutting-edge achievements also include two world firsts in the demonstrations of live cell chemical imaging using a benchtop device and intermediate band-gap solid-state solar cells.